Skip to main content
Top
Published in: Cancer Imaging 1/2024

Open Access 01-12-2024 | Mammography | Research article

Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trials

Authors: Sena Alaeikhanehshir, Madelon M. Voets, Frederieke H. van Duijnhoven, Esther H. lips, Emma J. Groen, Marja C. J. van Oirsouw, Shelley E. Hwang, Joseph Y. Lo, Jelle Wesseling, Ritse M. Mann, Jonas Teuwen, Grand Challenge PRECISION Consortium Steering Group

Published in: Cancer Imaging | Issue 1/2024

Login to get access

Abstract

Background

Ductal Carcinoma In Situ (DCIS) can progress to invasive breast cancer, but most DCIS lesions never will. Therefore, four clinical trials (COMET, LORIS, LORETTA, AND LORD) test whether active surveillance for women with low-risk Ductal carcinoma In Situ is safe (E. S. Hwang et al., BMJ Open, 9: e026797, 2019, A. Francis et al., Eur J Cancer. 51: 2296–2303, 2015, Chizuko Kanbayashi et al. The international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA),  L. E. Elshof et al., Eur J Cancer, 51, 1497–510, 2015). Low-risk is defined as grade I or II DCIS. Because DCIS grade is a major eligibility criteria in these trials, it would be very helpful to assess DCIS grade on mammography, informed by grade assessed on DCIS histopathology in pre-surgery biopsies, since surgery will not be performed on a significant number of patients participating in these trials.

Objective

To assess the performance and clinical utility of a convolutional neural network (CNN) in discriminating high-risk (grade III) DCIS and/or Invasive Breast Cancer (IBC) from low-risk (grade I/II) DCIS based on mammographic features. We explored whether the CNN could be used as a decision support tool, from excluding high-risk patients for active surveillance.

Methods

In this single centre retrospective study, 464 patients diagnosed with DCIS based on pre-surgery biopsy between 2000 and 2014 were included. The collection of mammography images was partitioned on a patient-level into two subsets, one for training containing 80% of cases (371 cases, 681 images) and 20% (93 cases, 173 images) for testing. A deep learning model based on the U-Net CNN was trained and validated on 681 two-dimensional mammograms. Classification performance was assessed with the Area Under the Curve (AUC) receiver operating characteristic and predictive values on the test set for predicting high risk DCIS-and high-risk DCIS and/ or IBC from low-risk DCIS.

Results

When classifying DCIS as high-risk, the deep learning network achieved a Positive Predictive Value (PPV) of 0.40, Negative Predictive Value (NPV) of 0.91 and an AUC of 0.72 on the test dataset. For distinguishing high-risk and/or upstaged DCIS (occult invasive breast cancer) from low-risk DCIS a PPV of 0.80, a NPV of 0.84 and an AUC of 0.76 were achieved.

Conclusion

For both scenarios (DCIS grade I/II vs. III, DCIS grade I/II vs. III and/or IBC) AUCs were high, 0.72 and 0.76, respectively, concluding that our convolutional neural network can discriminate low-grade from high-grade DCIS.
Literature
3.
15.
go back to reference Chizuko Kanbayashi HI, Thompson AM, Hwang E-SS, Partridge AH. Daniel William Rea, Jelle Wesseling, Tadahiko Shien, Tomonori Mizutani, Taro Shibata, the international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA). Chizuko Kanbayashi HI, Thompson AM, Hwang E-SS, Partridge AH. Daniel William Rea, Jelle Wesseling, Tadahiko Shien, Tomonori Mizutani, Taro Shibata, the international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA).
16.
go back to reference Elshof LE et al. Aug., Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study., Eur J Cancer, 51, 12, 1497–510, 2015, https://doi.org/10.1016/j.ejca.2015.05.008. Elshof LE et al. Aug., Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study., Eur J Cancer, 51, 12, 1497–510, 2015, https://​doi.​org/​10.​1016/​j.​ejca.​2015.​05.​008.
48.
go back to reference Ronneberger O, Fischer P, Brox T. U-Net: Convolutional Networks for Biomedical Image Segmentation, Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), vol. 9351, pp. 234–241, 2015, https://doi.org/10.1007/978-3-319-24574-4_28. Ronneberger O, Fischer P, Brox T. U-Net: Convolutional Networks for Biomedical Image Segmentation, Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), vol. 9351, pp. 234–241, 2015, https://​doi.​org/​10.​1007/​978-3-319-24574-4_​28.
49.
go back to reference Goodfellow A, Bengio I, Courville Y. Softmax Units for Multinoulli Output Distributions’’ Deep Learning, in ‘6.2.2.3 Softmax Units for Multinoulli Output Distributions’ Deep Learning, 2016, p. MIT Press. pp. 180–184. ISBN 978-0-26203561-3. Goodfellow A, Bengio I, Courville Y. Softmax Units for Multinoulli Output Distributions’’ Deep Learning, in ‘6.2.2.3 Softmax Units for Multinoulli Output Distributions’ Deep Learning, 2016, p. MIT Press. pp. 180–184. ISBN 978-0-26203561-3.
50.
go back to reference DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach., Biometrics, 44, 3, 837–45, Sep. 1988. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach., Biometrics, 44, 3, 837–45, Sep. 1988.
Metadata
Title
Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trials
Authors
Sena Alaeikhanehshir
Madelon M. Voets
Frederieke H. van Duijnhoven
Esther H. lips
Emma J. Groen
Marja C. J. van Oirsouw
Shelley E. Hwang
Joseph Y. Lo
Jelle Wesseling
Ritse M. Mann
Jonas Teuwen
Grand Challenge PRECISION Consortium Steering Group
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Imaging / Issue 1/2024
Electronic ISSN: 1470-7330
DOI
https://doi.org/10.1186/s40644-024-00691-x

Other articles of this Issue 1/2024

Cancer Imaging 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine